Collectively, our gene expression results signify that DSHT treatment regulates the expression of genes involved in NAFLD, fat digestion and absorption, insulin signaling pathway, PPAR signaling pathway, AMPK signaling pathway, metabolic pathway, steroid biosynthesis, terpenoid back-bone biosynthesis, low-protein partical and low-density lipoprotein binding and receptor activity. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.